Search This Blog

Friday, May 29, 2020

Forma Therapeutics on deck for IPO

Forma Therapeutics (FMTX) has filed a preliminary prospectus for a $150M IPO.
The Watertown, MA-based biopharmaceutical firm develops small molecule treatments for rare blood diseases and cancer. Lead candidate is FT-4202, an activator of an enzyme called  pyruvate kinase-R (PKR), for sickle cell disease. Deficient levels of PKR, located in red blood cells, are associated with chronic hemolysis (rupture or destruction of red blood cells).
2019 Financials: Collaboration Revenue: $100.6M (-39%); Operating Expenses: $141.0M (-9%); Net Loss: ($53.7M) (-999%); Cash Flow Ops: ($34.5M) (+74%).
https://seekingalpha.com/news/3578778-forma-therapeutics-on-deck-for-ipo

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.